Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans

X. Liang, J. Penagaricano, Dandan Zheng, S. Morrill, X. Zhang, P. Corry, R. J. Griffin, E. Y. Han, M. Hardee, V. Ratanatharathom

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT plans of SBRT treatmentsfor non-small-cell lung cancer (NSCLC) patients. Methods: Twenty eight patients with NSCLC previously treated SBRT were re-planned using Varian Eclipse (V11) with combined dose-volume and biological optimization IMRT sliding window technique. The total dose prescribed to the PTV was 60Gy with 12Gy per fraction. The plans were initially optimized using AAA algorithm, and then were recomputed using AXB using the same MUs and MLC files to compare with the dose distribution of the original plans and assess the radiobiological as well as dosimetric impact of the two different dose algorithms. The Poisson Linear-Quadatric (PLQ) and Lyman-Kutcher-Burman (LKB) models were used for estimating the tumor control probability (TCP) and normal tissue complication probability (NTCP), respectively. The influence of the model parameter uncertainties on the TCP differences and the NTCP differences between AAA and AXB plans were studied by applying different sets of published model parameters. Patients were grouped into peripheral and centrally-located tumors to evaluate the impact of tumor location. Results: PTV dose was lower in the re-calculated AXB plans, as compared to AAA plans. The median differences of PTV(D95%) were 1.7Gy (range: 0.3, 6.5Gy) and 1.0Gy (range: 0.6, 4.4Gy) for peripheral tumors and centrally-located tumors, respectively. The median differences of PTV(mean) were 0.4Gy (range: 0.0, 1.9Gy) and 0.9Gy (range: 0.0, 4.3Gy) for peripheral tumors and centrally-located tumors, respectively. TCP was also found lower in AXB-recalculated plans compared with the AAA plans. The median (range) of the TCP differences for 30month local control were 1.6% (0.3%, 5.8%) for peripheral tumors and 1.3% (0.5%, 3.4%) for centrally located tumors. The lower TCP is associated with the lower PTV coverage in AXB-recalculated plans. No obvious trend was observed between the calculation-resulted TCP differences and tumor size or location. AAA and AXB yield very similar NTCP on lung pneumonitis according to the LKB model estimation in the present study. Conclusion: AAA apparently overestimates the PTV dose the magnitude of resulting difference in calculated TCP was up to 5.8% in our study. AAA and AXB yield very similar NTCP on lung pneumonitis based on the LKB model parameter sets we used in the present study.

Original languageEnglish (US)
Article number10
JournalRadiation Oncology
Volume11
Issue number1
DOIs
StatePublished - Jan 22 2016

Fingerprint

Radiotherapy
Lung
Neoplasms
Non-Small Cell Lung Carcinoma
Pneumonia
Uncertainty

Keywords

  • AAA and AXB dose calculation algorithms
  • Combined dose-volume and biologically optimized IMRT
  • Fractioned stereotactic radiotherapy
  • Non-small-cell lung cancer
  • NTCP
  • TCP

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans. / Liang, X.; Penagaricano, J.; Zheng, Dandan; Morrill, S.; Zhang, X.; Corry, P.; Griffin, R. J.; Han, E. Y.; Hardee, M.; Ratanatharathom, V.

In: Radiation Oncology, Vol. 11, No. 1, 10, 22.01.2016.

Research output: Contribution to journalArticle

Liang, X, Penagaricano, J, Zheng, D, Morrill, S, Zhang, X, Corry, P, Griffin, RJ, Han, EY, Hardee, M & Ratanatharathom, V 2016, 'Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans', Radiation Oncology, vol. 11, no. 1, 10. https://doi.org/10.1186/s13014-015-0578-2
Liang, X. ; Penagaricano, J. ; Zheng, Dandan ; Morrill, S. ; Zhang, X. ; Corry, P. ; Griffin, R. J. ; Han, E. Y. ; Hardee, M. ; Ratanatharathom, V. / Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans. In: Radiation Oncology. 2016 ; Vol. 11, No. 1.
@article{889b5f588a08418ba1ddbd909d217842,
title = "Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans",
abstract = "Background: The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT plans of SBRT treatmentsfor non-small-cell lung cancer (NSCLC) patients. Methods: Twenty eight patients with NSCLC previously treated SBRT were re-planned using Varian Eclipse (V11) with combined dose-volume and biological optimization IMRT sliding window technique. The total dose prescribed to the PTV was 60Gy with 12Gy per fraction. The plans were initially optimized using AAA algorithm, and then were recomputed using AXB using the same MUs and MLC files to compare with the dose distribution of the original plans and assess the radiobiological as well as dosimetric impact of the two different dose algorithms. The Poisson Linear-Quadatric (PLQ) and Lyman-Kutcher-Burman (LKB) models were used for estimating the tumor control probability (TCP) and normal tissue complication probability (NTCP), respectively. The influence of the model parameter uncertainties on the TCP differences and the NTCP differences between AAA and AXB plans were studied by applying different sets of published model parameters. Patients were grouped into peripheral and centrally-located tumors to evaluate the impact of tumor location. Results: PTV dose was lower in the re-calculated AXB plans, as compared to AAA plans. The median differences of PTV(D95{\%}) were 1.7Gy (range: 0.3, 6.5Gy) and 1.0Gy (range: 0.6, 4.4Gy) for peripheral tumors and centrally-located tumors, respectively. The median differences of PTV(mean) were 0.4Gy (range: 0.0, 1.9Gy) and 0.9Gy (range: 0.0, 4.3Gy) for peripheral tumors and centrally-located tumors, respectively. TCP was also found lower in AXB-recalculated plans compared with the AAA plans. The median (range) of the TCP differences for 30month local control were 1.6{\%} (0.3{\%}, 5.8{\%}) for peripheral tumors and 1.3{\%} (0.5{\%}, 3.4{\%}) for centrally located tumors. The lower TCP is associated with the lower PTV coverage in AXB-recalculated plans. No obvious trend was observed between the calculation-resulted TCP differences and tumor size or location. AAA and AXB yield very similar NTCP on lung pneumonitis according to the LKB model estimation in the present study. Conclusion: AAA apparently overestimates the PTV dose the magnitude of resulting difference in calculated TCP was up to 5.8{\%} in our study. AAA and AXB yield very similar NTCP on lung pneumonitis based on the LKB model parameter sets we used in the present study.",
keywords = "AAA and AXB dose calculation algorithms, Combined dose-volume and biologically optimized IMRT, Fractioned stereotactic radiotherapy, Non-small-cell lung cancer, NTCP, TCP",
author = "X. Liang and J. Penagaricano and Dandan Zheng and S. Morrill and X. Zhang and P. Corry and Griffin, {R. J.} and Han, {E. Y.} and M. Hardee and V. Ratanatharathom",
year = "2016",
month = "1",
day = "22",
doi = "10.1186/s13014-015-0578-2",
language = "English (US)",
volume = "11",
journal = "Radiation Oncology",
issn = "1748-717X",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans

AU - Liang, X.

AU - Penagaricano, J.

AU - Zheng, Dandan

AU - Morrill, S.

AU - Zhang, X.

AU - Corry, P.

AU - Griffin, R. J.

AU - Han, E. Y.

AU - Hardee, M.

AU - Ratanatharathom, V.

PY - 2016/1/22

Y1 - 2016/1/22

N2 - Background: The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT plans of SBRT treatmentsfor non-small-cell lung cancer (NSCLC) patients. Methods: Twenty eight patients with NSCLC previously treated SBRT were re-planned using Varian Eclipse (V11) with combined dose-volume and biological optimization IMRT sliding window technique. The total dose prescribed to the PTV was 60Gy with 12Gy per fraction. The plans were initially optimized using AAA algorithm, and then were recomputed using AXB using the same MUs and MLC files to compare with the dose distribution of the original plans and assess the radiobiological as well as dosimetric impact of the two different dose algorithms. The Poisson Linear-Quadatric (PLQ) and Lyman-Kutcher-Burman (LKB) models were used for estimating the tumor control probability (TCP) and normal tissue complication probability (NTCP), respectively. The influence of the model parameter uncertainties on the TCP differences and the NTCP differences between AAA and AXB plans were studied by applying different sets of published model parameters. Patients were grouped into peripheral and centrally-located tumors to evaluate the impact of tumor location. Results: PTV dose was lower in the re-calculated AXB plans, as compared to AAA plans. The median differences of PTV(D95%) were 1.7Gy (range: 0.3, 6.5Gy) and 1.0Gy (range: 0.6, 4.4Gy) for peripheral tumors and centrally-located tumors, respectively. The median differences of PTV(mean) were 0.4Gy (range: 0.0, 1.9Gy) and 0.9Gy (range: 0.0, 4.3Gy) for peripheral tumors and centrally-located tumors, respectively. TCP was also found lower in AXB-recalculated plans compared with the AAA plans. The median (range) of the TCP differences for 30month local control were 1.6% (0.3%, 5.8%) for peripheral tumors and 1.3% (0.5%, 3.4%) for centrally located tumors. The lower TCP is associated with the lower PTV coverage in AXB-recalculated plans. No obvious trend was observed between the calculation-resulted TCP differences and tumor size or location. AAA and AXB yield very similar NTCP on lung pneumonitis according to the LKB model estimation in the present study. Conclusion: AAA apparently overestimates the PTV dose the magnitude of resulting difference in calculated TCP was up to 5.8% in our study. AAA and AXB yield very similar NTCP on lung pneumonitis based on the LKB model parameter sets we used in the present study.

AB - Background: The aim of this study is to evaluate the radiobiological impact of Acuros XB (AXB) vs. Anisotropic Analytic Algorithm (AAA) dose calculation algorithms in combined dose-volume and biological optimized IMRT plans of SBRT treatmentsfor non-small-cell lung cancer (NSCLC) patients. Methods: Twenty eight patients with NSCLC previously treated SBRT were re-planned using Varian Eclipse (V11) with combined dose-volume and biological optimization IMRT sliding window technique. The total dose prescribed to the PTV was 60Gy with 12Gy per fraction. The plans were initially optimized using AAA algorithm, and then were recomputed using AXB using the same MUs and MLC files to compare with the dose distribution of the original plans and assess the radiobiological as well as dosimetric impact of the two different dose algorithms. The Poisson Linear-Quadatric (PLQ) and Lyman-Kutcher-Burman (LKB) models were used for estimating the tumor control probability (TCP) and normal tissue complication probability (NTCP), respectively. The influence of the model parameter uncertainties on the TCP differences and the NTCP differences between AAA and AXB plans were studied by applying different sets of published model parameters. Patients were grouped into peripheral and centrally-located tumors to evaluate the impact of tumor location. Results: PTV dose was lower in the re-calculated AXB plans, as compared to AAA plans. The median differences of PTV(D95%) were 1.7Gy (range: 0.3, 6.5Gy) and 1.0Gy (range: 0.6, 4.4Gy) for peripheral tumors and centrally-located tumors, respectively. The median differences of PTV(mean) were 0.4Gy (range: 0.0, 1.9Gy) and 0.9Gy (range: 0.0, 4.3Gy) for peripheral tumors and centrally-located tumors, respectively. TCP was also found lower in AXB-recalculated plans compared with the AAA plans. The median (range) of the TCP differences for 30month local control were 1.6% (0.3%, 5.8%) for peripheral tumors and 1.3% (0.5%, 3.4%) for centrally located tumors. The lower TCP is associated with the lower PTV coverage in AXB-recalculated plans. No obvious trend was observed between the calculation-resulted TCP differences and tumor size or location. AAA and AXB yield very similar NTCP on lung pneumonitis according to the LKB model estimation in the present study. Conclusion: AAA apparently overestimates the PTV dose the magnitude of resulting difference in calculated TCP was up to 5.8% in our study. AAA and AXB yield very similar NTCP on lung pneumonitis based on the LKB model parameter sets we used in the present study.

KW - AAA and AXB dose calculation algorithms

KW - Combined dose-volume and biologically optimized IMRT

KW - Fractioned stereotactic radiotherapy

KW - Non-small-cell lung cancer

KW - NTCP

KW - TCP

UR - http://www.scopus.com/inward/record.url?scp=84960122633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960122633&partnerID=8YFLogxK

U2 - 10.1186/s13014-015-0578-2

DO - 10.1186/s13014-015-0578-2

M3 - Article

VL - 11

JO - Radiation Oncology

JF - Radiation Oncology

SN - 1748-717X

IS - 1

M1 - 10

ER -